# Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

> **NCT00982488** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 238 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT00982488
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 238 (ACTUAL)
- **Last updated:** 2016-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00982488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00982488, "Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00982488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*